Known targets — ChEMBL curated mechanism
ADRA2AADRA2BADRA2CADRB2AGTR1AVPR1AAVPR1BAVPR2BDKRB2CALCRCHRNA3CHRNB4ESR1ESR2GHSRGNRHRGSC1HSPA8MALT1MC1RMC4RNOS1NOS2NOS3OPRK1OXTRRAMP1RAMP2RAMP3SCN5ASSTR1SSTR2SSTR3SSTR4SSTR5dacAdacBdacCfolPftsImrcAmrcBmrdArplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Quercetin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AVPR2 known ✓ | P30518 | 1/20 | 0.87 |
| ▸ | OPRK1 known ✓ | P41145 | 1/20 | 0.87 |
| ▸ | MEN1 | O00255 | 9/20 | 0.87 |
| ▸ | KMT2A | Q03164 | 9/20 | 0.87 |
| ▸ | CYP1A2 | P05177 | 8/20 | 0.87 |
| ▸ | CYP1A1 | P04798 | 7/20 | 0.87 |
| ▸ | CYP1B1 | Q16678 | 7/20 | 0.87 |
| ▸ | CYP3A4 | P08684 | 6/20 | 0.87 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.87 |
| ▸ | HSD17B10 | Q99714 | 6/20 | 0.87 |
| ▸ | MAPT | P10636 | 6/20 | 0.87 |
| ▸ | POLH | Q9Y253 | 6/20 | 0.87 |
| ▸ | ABCB1 | P08183 | 6/20 | 0.87 |
| ▸ | CYP2C9 | P11712 | 5/20 | 0.87 |
| ▸ | RECQL | P46063 | 5/20 | 0.87 |
| ▸ | IPMK | Q8NFU5 | 5/20 | 0.87 |
| ▸ | IP6K2 | Q9UHH9 | 5/20 | 0.87 |
| ▸ | XDH | P47989 | 5/20 | 0.87 |
| ▸ | FTO | Q9C0B1 | 5/20 | 0.87 |
| ▸ | ALOX15 | P16050 | 4/20 | 0.87 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Quercetin SCHEMBL5126185 | 1.00 | MEN1 (0.87) | MEN1KMT2ACYP1A2CYP1A1CYP1B1 | |
| Quercetin SCHEMBL27746111 | 0.93 | MEN1 (0.94) | MEN1KMT2ACYP1A2CYP1A1CYP1B1 | |
| Quercetin SCHEMBL29351036 | 0.93 | MEN1 (1.00) | MEN1KMT2ACYP1A2CYP1A1CYP1B1 | |
| Quercetin SCHEMBL19723 | 0.93 | MEN1 (1.00) | MEN1KMT2ACYP1A2CYP1A1CYP1B1 | |
| Quercetin SCHEMBL29353785 | 0.93 | MEN1 (1.00) | MEN1KMT2ACYP1A2CYP1A1CYP1B1 | |
| Quercetin SCHEMBL17629824 | 0.93 | MEN1 (1.00) | MEN1KMT2ACYP1A2CYP1A1CYP1B1 | |
| Quercetin SCHEMBL118425 | 0.93 | MEN1 (1.00) | MEN1KMT2ACYP1A2CYP1A1CYP1B1 | |
| Quercetin SCHEMBL29723041 | 0.93 | MEN1 (1.00) | MEN1KMT2ACYP1A2CYP1A1CYP1B1 | |
| Quercetin SCHEMBL31507620 | 0.93 | MEN1 (1.00) | MEN1KMT2ACYP1A2CYP1A1CYP1B1 | |
| Quercetin SCHEMBL11298145 | 0.93 | MEN1 (0.79) | MEN1KMT2ACYP1A2CYP1A1CYP1B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-105503804-A | Synthesis of quercetin-3-O-acetate and application of quercetin-3-O-acetate to tumor resistance | WENZHOU FANGZHI BIOTECHNOLOGY CO LTD | 2016-04-20 | — | — | CN | claimed |
| US-5607921-A | Stabilized cosmetic or dermatological composition containing several precursors of the same active agent in order to maximize its release, and use thereof | L'OREAL (FR) | 1997-03-04 | — | — | US | claimed |
| CN-118453424-A | Antibacterial stain-removing activated carbon toothpaste and preparation method thereof | 海南椰漾生物科技有限公司 | 2024-08-09 | — | — | CN | disclosed |
| CN-105503804-B | The synthesis and the application in anti-tumor aspect of the O acetic acid esters of Quercetin 3 | 温州芳植生物科技有限公司 | 2017-10-13 | — | — | CN | disclosed |
| CN-105503804-A | Synthesis of quercetin-3-O-acetate and application of quercetin-3-O-acetate to tumor resistance | WENZHOU FANGZHI BIOTECHNOLOGY CO LTD | 2016-04-20 | — | — | CN | disclosed |
| CN-102762111-A | Sweetness enhancers, compositions thereof, and methods of use | COCA COLA CO | 2012-10-31 | — | — | CN | disclosed |
| WO-2003105806-A1 | STABILIZED RETINOL FOR COSMETIC DERMATOLOGICAL, AND PHARMACEUTICAL COMPOSITIONS, AND USE THEREOF | SALVONA L.L.C. (US) | 2003-12-24 | — | — | WO | disclosed |
| US-20030232091-A1 | Stabilized retinol for cosmetic dermatological, and pharmaceutical compositions, and use thereof | SHEFER ADI (US) | 2003-12-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030232091-A1 | Stabilized retinol for cosmetic dermatological, and pharmaceutical compositions, and use thereof | RBP4, RBP1, RARA | AVPR2 3435/4885OPRK1 3997/4885MEN1 4402/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.